Clinical Trial Update: Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing how CYP2C19 genetic variation affects Helicobacter pylori eradication therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Snippet

Sponsor: Javeriana University | Conditions: CYP2C19 Polymorphism, H.Pylori Infection | Phase 4 | Status: COMPLETED